Contact
searchSearch
HMP Global

Pharmacy Learning Network

PharmLaw

PharmLaw
Monogram Health to Pay $2.4 Million to Settle Medicare Advantage False Claims Allegations
08/26/2026
Grace Taylor, MS, MA
Monogram Health has agreed to pay $2.4 million to settle federal allegations that unsupported diagnosis codes led to increased Medicare Advantage payments.
Monogram Health has agreed to pay $2.4 million to settle federal allegations that unsupported diagnosis codes led to increased Medicare Advantage payments.
Monogram Health has agreed to...
08/26/2026
Pharmacy Learning Network
PharmLaw
AstraZeneca Challenges Illinois 340B Contract Pharmacy Law in Federal Court
08/19/2026
Hannah Musick
AstraZeneca has joined AbbVie and Novartis in challenging Illinois’ new 340B contract pharmacy law, adding to a growing national legal battle over state authority to regulate manufacturer distribution requirements and compliance data within...
AstraZeneca has joined AbbVie and Novartis in challenging Illinois’ new 340B contract pharmacy law, adding to a growing national legal battle over state authority to regulate manufacturer distribution requirements and compliance data within...
AstraZeneca has joined AbbVie...
08/19/2026
Pharmacy Learning Network
PharmLaw
Eli Lilly Files Lawsuits Targeting Alleged Sales of Unapproved Retatrutide
08/12/2026
Hannah Musick
Eli Lilly has filed 6 lawsuits against companies allegedly selling unapproved versions of investigational obesity drug retatrutide, highlighting growing legal and regulatory scrutiny of unauthorized products entering the rapidly expanding...
Eli Lilly has filed 6 lawsuits against companies allegedly selling unapproved versions of investigational obesity drug retatrutide, highlighting growing legal and regulatory scrutiny of unauthorized products entering the rapidly expanding...
Eli Lilly has filed 6 lawsuits...
08/12/2026
Pharmacy Learning Network
PharmLaw
Arkansas Suspends Enforcement of Specialty Drug Distribution Law Following Constitutional Challenge
08/05/2026
Hannah Musick
The Arkansas State Board of Pharmacy has suspended enforcement of a law restricting manufacturers' use of limited drug distribution networks after a federal court found the statute likely violates the dormant Commerce Clause, setting up a...
The Arkansas State Board of Pharmacy has suspended enforcement of a law restricting manufacturers' use of limited drug distribution networks after a federal court found the statute likely violates the dormant Commerce Clause, setting up a...
The Arkansas State Board of...
08/05/2026
Pharmacy Learning Network
PharmLaw
EyePoint Pharmaceuticals Agrees to $4.6 Million False Claims Act Settlement
07/29/2026
Grace Taylor, MS, MA
EyePoint Pharmaceuticals has agreed to pay $4.6 million to resolve False Claims Act allegations involving DEXYCU marketing practices, highlighting continued federal scrutiny of pharmaceutical manufacturer programs under the Anti-Kickback...
EyePoint Pharmaceuticals has agreed to pay $4.6 million to resolve False Claims Act allegations involving DEXYCU marketing practices, highlighting continued federal scrutiny of pharmaceutical manufacturer programs under the Anti-Kickback...
EyePoint Pharmaceuticals has...
07/29/2026
Pharmacy Learning Network

FDA Recalls

News
Cemiplimab Injection Recalled Due to Lack of Sterility Assurance
08/27/2026
Rebecca Amrick
Libtayo (cemiplimab-rwlc) injection is under a voluntary Class II recall due to a lack of assurance of the product’s sterility, affecting 21 353 vials.
Libtayo (cemiplimab-rwlc) injection is under a voluntary Class II recall due to a lack of assurance of the product’s sterility, affecting 21 353 vials.
Libtayo (cemiplimab-rwlc)...
08/27/2026
Pharmacy Learning Network
News
Acamprosate Calcium Tablets Recalled Due to Failed Dissolution Specifications
08/27/2026
Rebecca Amrick
A voluntary Class II recall has been issued for acamprosate calcium tablets due to the product’s failure to meet dissolution specifications.
A voluntary Class II recall has been issued for acamprosate calcium tablets due to the product’s failure to meet dissolution specifications.
A voluntary Class II recall has...
08/27/2026
Pharmacy Learning Network
News
Morphine Injection Recalled Due to Labeling Mix-Up
08/27/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall for morphine sulfate injection due to a mistake in product labeling, affecting 625 500 syringes.
The US Food and Drug Administration (FDA) has issued a Class I recall for morphine sulfate injection due to a mistake in product labeling, affecting 625 500 syringes.
The US Food and Drug...
08/27/2026
Pharmacy Learning Network
News
Valsartan Tablets Recalled Due to Failed Dissolution Specifications
08/20/2026
Rebecca Amrick
Diovan (valsartan) tablets are under a voluntary Class II recall after failing to meet dissolution specifications.
Diovan (valsartan) tablets are under a voluntary Class II recall after failing to meet dissolution specifications.
Diovan (valsartan) tablets are...
08/20/2026
Pharmacy Learning Network
News
Clindamycin Palmitate Hydrochloride Recalled Due to the Presence of Foreign Substance
08/20/2026
Rebecca Amrick
A voluntary Class II recall has been issued for clindamycin palmitate hydrochloride oral solution due to the presence of foreign particles in the product.
A voluntary Class II recall has been issued for clindamycin palmitate hydrochloride oral solution due to the presence of foreign particles in the product.
A voluntary Class II recall has...
08/20/2026
Pharmacy Learning Network

In the News

News
Cemiplimab Injection Recalled Due to Lack of Sterility Assurance
08/27/2026
Rebecca Amrick
Libtayo (cemiplimab-rwlc) injection is under a voluntary Class II recall due to a lack of assurance of the product’s sterility, affecting 21 353 vials.
Libtayo (cemiplimab-rwlc) injection is under a voluntary Class II recall due to a lack of assurance of the product’s sterility, affecting 21 353 vials.
Libtayo (cemiplimab-rwlc)...
08/27/2026
Pharmacy Learning Network
News
Acamprosate Calcium Tablets Recalled Due to Failed Dissolution Specifications
08/27/2026
Rebecca Amrick
A voluntary Class II recall has been issued for acamprosate calcium tablets due to the product’s failure to meet dissolution specifications.
A voluntary Class II recall has been issued for acamprosate calcium tablets due to the product’s failure to meet dissolution specifications.
A voluntary Class II recall has...
08/27/2026
Pharmacy Learning Network
News
Morphine Injection Recalled Due to Labeling Mix-Up
08/27/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall for morphine sulfate injection due to a mistake in product labeling, affecting 625 500 syringes.
The US Food and Drug Administration (FDA) has issued a Class I recall for morphine sulfate injection due to a mistake in product labeling, affecting 625 500 syringes.
The US Food and Drug...
08/27/2026
Pharmacy Learning Network
PharmLaw
Monogram Health to Pay $2.4 Million to Settle Medicare Advantage False Claims Allegations
08/26/2026
Grace Taylor, MS, MA
Monogram Health has agreed to pay $2.4 million to settle federal allegations that unsupported diagnosis codes led to increased Medicare Advantage payments.
Monogram Health has agreed to pay $2.4 million to settle federal allegations that unsupported diagnosis codes led to increased Medicare Advantage payments.
Monogram Health has agreed to...
08/26/2026
Pharmacy Learning Network
News
Valsartan Tablets Recalled Due to Failed Dissolution Specifications
08/20/2026
Rebecca Amrick
Diovan (valsartan) tablets are under a voluntary Class II recall after failing to meet dissolution specifications.
Diovan (valsartan) tablets are under a voluntary Class II recall after failing to meet dissolution specifications.
Diovan (valsartan) tablets are...
08/20/2026
Pharmacy Learning Network

Subscribe Today

Pharmacy Learning Network Newsletter

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use